摘要
目的观察吉非替尼治疗晚期非小细胞肺癌(NSCLC)临床疗效与外周T淋巴细胞亚群变化的关系。方法对组织或细胞病理证实的35例晚期NSCLC患者口服吉非替尼250 mg/d。采集全部患者治疗前及治疗后外周血标本,三色染色后流式细胞仪分析CD3+、CD4+、CD8+T淋巴细胞亚群变化。结果35例患者中部分缓解13例,稳定13例,进展9例,疾病控制率为74.2%。治疗前后T淋巴细胞亚群无显著差异。结论吉非替尼治疗晚期非小细胞肺癌疗效较好,毒副反应轻微。治疗后T淋巴细胞可以恢复到治疗前水平。
Objective To analyze the effects of Gefitinib on patients with advanced non-small cell lung cancer （NSCLC） and the effect on T lymphocyte subsets. Methods A total of 35 patients with NSCLC confirmed by pathology or cytology administered orally 250 mg of Gefitinib once a day. Three-color fluorescent flow cytometry were used to analyze the percentage of CD3＋ , CD4＋ , and CD8＋ T lymphocyte in peripheral blood before and after the treatment. Results No complete response （CR） was achieved. At the same time, there were 13 cases with partial response （PR）, 13 cases with stable disease （SD）, and 9 with progressed disease （PD）. The disease control rate （CR＋PR＋SD） was 74.2%. There was not signi- ficant difference in the variations of T lymphocyte subsets before and after the treatment. Conclusion Gefitinib is very effective in the treatment of patients with advanced NSCLC, with minimal side effects. The percentage of CD3＋ , CD4＋ , and CD8＋ T lymphocyte in peripheral blood after the treatment can be returned to that of pre-treatment.
出处
《现代药物与临床》
CAS
2009年第5期298-300,共3页
Drugs & Clinic
